Blood Research  2013;48(1):68-69

doi:10.5045/br.2013.48.1.68

Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome.

Chul Won JUNG 1

Affiliations

+expand

Country

Republic of Korea

Language

English

Abstract

No abstract available.